中国肺癌杂志2024，Vol.27Issue(11)：855-863,9.DOI:10.3779/j.issn.1009-3419.2024.102.35
广泛期小细胞肺癌免疫治疗:研究进展和未来展望
Immunotherapy for Extensive-stage Small Cell Lung Cancer:Research Progress and Future Perspectives
摘要
Abstract
At present,immunotherapy combined with chemotherapy has become the first-line standard of treat-ment for extensive-stage small cell lung cancer(ES-SCLC).In recent years,immune checkpoint inhibitors(ICIs)have received extensive attention and research in the field of lung cancer.At the same time,there are many challenges and tests in this process,such as the exploration of biomarkers,the exploration of new targets and new models,and the management of special popula-tions.This article reviews the research progress in the field of ES-SCLC immunotherapy,and looks forward to the future devel-opment trend and potential direction of this field.关键词
肺肿瘤/免疫治疗/免疫检查点抑制剂/生物标志物Key words
Lung neoplasms/Immunotherapy/Immune checkpoint inhibitors/Biomarkers引用本文复制引用
钟雨玲,王婧怡,邬麟..广泛期小细胞肺癌免疫治疗:研究进展和未来展望[J].中国肺癌杂志,2024,27(11):855-863,9.基金项目
本文受国家临床重点专科重大科研专项(No.Z2023098)、湖南省卫生健康高层次人才重大科研专项(No.R2023125)、湖南省科技创新计划(No.2023SK4024、No.2021SK51121)、湖南省肿瘤医院"科研攀登计划"(No.ZX2020005-5)、北京市希思科临床肿瘤学研究基金会(No.Y-2019Genecast-024)资助 This paper was supported by the grants from National Key Clinical Specialty Scientific Research Project(No.Z2023098),Hunan Provincial Health High-level Talent Scientific Research Project(No.R2023125),Science and Technol-ogy Innovation Program of Hunan Province(No.2023SK4024,No.2021SK51121),Hunan Cancer Hospital Climb Plan(No.ZX2020005-5)and Beijing Xisike Clinical Oncology Research Foundation(No.Y-2019Genecast-024)(All to Lin WU). （No.Z2023098）
